Cyproheptadine Zydus
1-Methyl-4-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,9,11,13-heptaenylidene)piperidine
Drag to rotate; arrow keys step through the atoms. Structure from PubChem CID 2913.
Registration
- Applicants
- 1
- Registrations
- 1
Applicants and registrations
| Applicant | Brands | Dosages | Registrations | Schedule | Leaflets |
|---|---|---|---|---|---|
| Zydus Healthcare (Pty) Ltd | Cyproheptadine zydus | Not stated | 550848.847 | Not determined | None |
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Cyproheptadine zydus EACH TABLET CONTAINS CYPROHEPTADINE HYDROCHLORIDE EQUIVALENT TO CYPROHEPTADINE 4,0 mg | Not listed | 550848.84755/5.7.1/0848.847 | Registered | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S5: Cyproheptadine
- except when indicated for allergic rhinitis or antipruritic use.
Consolidated Schedules 06 July 2026, line 9349
S2: Cyproheptadine
- when indicated for allergic rhinitis or antipruritic use.
Consolidated Schedules 06 July 2026, line 1789
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
Background
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.